Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial

被引:363
作者
Sasako, Mitsuru [1 ]
Sano, Takeshi
Yamamoto, Seiichiro
Sairenji, Motonri
Arai, Kuniyoshi
Kinoshita, Taira
Nashimoto, Atsushi
Hiratsuka, Masahiro
机构
[1] Natl Canc Ctr, Tokyo, Japan
[2] Kanagawa Canc Ctr, Kanagawa, Japan
[3] Metropolitan Komagome Hosp, Tokyo, Japan
[4] Natl Canc Ctr E Hosp, Kashiwa, Chiba, Japan
[5] Niigata Canc Ctr Hosp, Niigata, Japan
[6] Osaka Med Ctr Canc & Cardiovasc Dis, Osaka, Japan
关键词
D O I
10.1016/S1470-2045(06)70766-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Because of the inaccessibility of mediastinal nodal metastases, the left thoracoabdominal approach (LTA) has often been used to treat gastric cancer of the cardia or subcardia. in a randomised phase III study, we aimed to compare LTA with the abdominal-transhiatal approach (TH) in the treatment of these tumours. Methods Between July, 1995, and December, 2003,167 patients were enrolled from 27 Japanese hospitals and randomly assigned to TH (n=82) or LTA (n=85). The primary endpoint was overall survival, and secondary endpoints were disease-free survival, postoperative morbidity and hospital mortality, and postoperative symptoms and change of respiratory function. The projected sample size was 302. After the first interim analysis, the predicted probability of LTA having a significantly better overall survival than TH at the final analysis was only 3.65%, and the trial was closed immediately. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00149266. Findings 5-year overall survival was 52.3% (95% CI 40.4-64. 1) in the TH group and 37.9% (26.1-49.6) in the LTA group. The hazard ratio of death for LTA compared with TH was 1.36 (0.89-2.08, p=0.92). Three patients died in hospital after LTA but none after TH. Morbidity was worse after LTA than after TH. Interpretation Because LTA does not improve survival after TH and leads to increased morbidity in patients with cancer of the cardia. or subcardia, LTA cannot be justified to treat these tumours.
引用
收藏
页码:644 / 651
页数:8
相关论文
共 32 条
  • [1] Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: Degree of pathologic response and not clinical parameters dictated patient outcome
    Ajani, JA
    Mansfield, PF
    Crane, CH
    Wu, TT
    Lunagomez, S
    Lynch, PM
    Janjan, N
    Feig, B
    Faust, J
    Yao, JC
    Nivers, R
    Morris, J
    Pisters, PW
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (06) : 1237 - 1244
  • [2] [Anonymous], 1995, JAP CLASS GASTR CARC
  • [3] Bayesian clinical trials
    Berry, DA
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (01) : 27 - 36
  • [4] RISING INCIDENCE OF ADENOCARCINOMA OF THE ESOPHAGUS AND GASTRIC CARDIA
    BLOT, WJ
    DEVESA, SS
    KNELLER, RW
    FRAUMENI, JF
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 265 (10): : 1287 - 1289
  • [5] Cunningham D, 2005, J CLIN ONCOL, V23, p308S
  • [6] INTERIM ANALYSIS - THE ALPHA-SPENDING FUNCTION-APPROACH
    DEMETS, DL
    LAN, KKG
    [J]. STATISTICS IN MEDICINE, 1994, 13 (13-14) : 1341 - 1352
  • [7] The pattern of metastatic lymph node dissemination from adenocarcinoma of the esophagogastric junction
    Dresner, SM
    Lamb, PJ
    Bennett, MK
    Hayes, N
    Griffin, SM
    [J]. SURGERY, 2001, 129 (01) : 103 - 109
  • [8] Hansen S, 1997, INT J CANCER, V71, P340, DOI 10.1002/(SICI)1097-0215(19970502)71:3<340::AID-IJC5>3.0.CO
  • [9] 2-Y
  • [10] HATTORI T, 1980, GANN, V71, P280